Management of patients with cirrhosis in Southern California: Results of a practitioner survey

Journal of Clinical Gastroenterology

Volumn 40, Issue 2, 2006, Pages 156-161

  Saab, Sammy ^a,d   Nguyen, Stephen ^a   Ibrahim, Ayman ^a   Vierling, John M ^b   Tong, Myron J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Liver cirrhosis; Practice guidelines; Screening

Indexed keywords

ALPHA FETOPROTEIN; AMILORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DIURETIC AGENT; FUROSEMIDE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HYDROCHLOROTHIAZIDE; INFLUENZA VACCINE; LACTULOSE; LEVOFLOXACIN; NEOMYCIN; NITRATE; NORFLOXACIN; PARACETAMOL; PNEUMOCOCCUS VACCINE; PROTEIN; QUINOLONE DERIVATIVE; SPIRONOLACTONE;

ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL PERITONITIS; CANCER SCREENING; DRUG CONTRAINDICATION; ENDOSCOPY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS VARICES; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL SOCIETY; NORMAL HUMAN; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRIVATE PRACTICE; PUBLIC HEALTH; QUESTIONNAIRE; REVIEW; ULTRASOUND; UNITED STATES; VACCINATION; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; FEMALE; MALE; STATISTICS;

CALIFORNIA; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 33645824160     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000196189.65167.53     Document Type: Review

References (50)

1. Anderson R, Smith B. Deaths: Leading causes for 2001. In: National Vital Statistics Reports [DHHS publication no. (PHS) 2004-1120], vol. 52, no. 9. Hyattsville, MD: National Center for Health Statistics, 2003.
2. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39.
3. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant. 2004;4:686-693.
4. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-1219.
5. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048-1058.
6. Saab S, Han SH, Martin P. Liver transplantation: selection, listing criteria, and preoperative management. Clin Liver Dis. 2000;4:513-532.
7. de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis. 2001;5:645-663.
8. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50.
9. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology. 1997;44:1404-1406.
10. Féray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology. 1993;104:549-555.
11. Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Cancer. 1994;74:2442-2448.
12. Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:38-41.
13. Ilan Y, Ashur Y, Tur-Kaspa R, et al. Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr J Med Sci. 1994;30:259-263.
14. Yao G. Clinical spectrum and natural history of viral hepatitis in a 1988 Shanghai epidemic. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore: Lippincott Williams & Wilkins, 1991:76-78.
15. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90:201-205.
16. Vento S, Garofano T, Renzine C, et al. Fulminant hepatitis associated with hepatitis A virus super infection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286-290.
17. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med. 1989;110:838-839.
18. Centers for Disease Control and Prevention, prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-37.
19. Tacket CO, Brenner F, Blake PA. Clinical features and an epidemiological study of Vibrio vulnificus infections. J Infect Dis. 1984;149:558-561.
20. Whitman CM, Griffin PM. Preventing Vibrio vulnificus infection in the high-risk patient. Infect Dis Clin Pract. 1993;2:275-276.
21. Centers for Disease Control and Prevention. Vibrio vulnificus infections associated with eating raw oysters-Los Angeles, 1996. MMWR. 1996;45:621-624.
22. Nevins CL, Malaty H, Velez ME, et al. Interaction of alcohol and hepatitis C virus infection on severity of liver disease. Dig Dis Sci. 1999;44:1236-1242.
23. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832.
24. Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther. 2003;17:1031-1037.
25. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat. 2002;9:235-241.
26. Food and Drug Administration. If You Eat Raw Oysters, You Need to Know [DHHS publication no. (FDA) 95-2293]. Washington, DC: U.S. Department of Health and Human Services, Public Health Service, 1995.
27. Mouzin E, Mascola L, Tormey MP, et al. Prevention of Vibrio vulnificus infections: assessment of regulatory educational strategies. JAMA. 1997;278:576-578.
28. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the ACIP. MMWR. 1997;46:1-32.
29. Centers for Disease Control and Prevention: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49:1-13.
30. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33:846-852.
31. Runyon BA. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD): management of adult patients with ascites due to cirrhosis. Hepatology. 2004;39:841-856.
32. Bruix J, Sherman M, Llovet JM, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
33. National Institutes of Health Consensus Development Conference Panel Statement. Management of Hepatitis C 2002. Hepatology. 2002;36(suppl):3-21.
34. Blei AT, Cordoba J. Practice Parameters Committee of the American College of Gastroenterology: hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968-1976.
35. Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94:2224-2229.
36. Zaman A, Hapke RJ, Flora K, et al. Changing compliance to the American College of Gastroenterology guidelines for the management of variceal hemorrhage: a regional survey. Am J Gastroenterol. 2004;99:645-649.
37. Shehab TM, Orrego M, Chunduri R, et al. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol. 2003;98:639-644.
38. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569.
39. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331-338.
40. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076-1084.
41. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273-278.
42. Saab S, Ly D, Nieto J, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl. 2003;9:672-681.
43. Arguedas MR, Chen VK, Eloubeidi MA, et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679-690.
44. McMahon BJ, London T. Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst. 1991;83:916-919.
45. Colombo M. Hepatocellular carcinoma. J Hepatol. 1992;15:225-236.
46. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-721.
47. Dhiman RK, Chawla YK. Minimal hepatic encephalopathy: should we start treating it? Gastroenterology. 2004;127:1855-1857.
48. Saab S, Ibrahim AB, Shpaner A, et al. Association between liver disease severity and quality of life in liver transplant candidates. Liver Transpl. 2005;11:218-223.
49. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci. 2003;48:1622-1626.
50. Wang V, Saab S. Liver transplantation in the era of model for end-stage liver disease. Liver Int. 2004;24:1-8.